Piramal Pharma’s Q1 revenue dipped 1% YoY, with EBITDA down 26% and higher losses due to inventory destocking.

• CDMO segment showed mid-teen revenue growth, excluding the impact from a major product’s destocking.
• Consumer business grew steadily, led by strong performance in power brands and e-commerce channels.
• Company eyes $2B revenue and 25% EBITDA margin by FY2030 despite near-term operational challenges.